Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Proscia Named To Inc.’s Best In Business List

Proscia
By Proscia | December 9, 2020

At Proscia, making a difference in the lives of cancer patients is the driving force behind our mission. And it’s why we’re especially proud to be named to Inc.’s inaugural Best in Business.

Inc.’s list celebrates small- and medium-size companies that have had a superlative impact – whether on their communities, their industries, or society as a whole. Companies on the list are tackling today’s biggest problems to drive towards a better future.

Proscia was awarded a silver medal for our work helping the Joint Pathology Center unleash a transformative wave of biomedical research. JPC, the premiere pathology reference center for the U.S. government, turned to Proscia to modernize the world’s largest repository of human tissue data and drive advances related to our understanding of cancer and other infectious diseases. 

This is just one of the many ways that we’re transforming the practice of pathology. While pathology sits at the core of biomedical research and cancer diagnosis, it has remained largely unchanged in its 150-year history, depending solely on the human eye recognizing patterns in tissue under the microscope. By digitizing this practice, we’re not only enabling organizations like JPC to unlock new insights but also empowering laboratories, health systems, and life sciences companies to accelerate breakthroughs and improve patient outcomes. 

Driving this disruptive change takes an incredible team of pioneers and visionaries coming together to solve problems the world has never solved before. On the heels of our $23M Series B, we’re rapidly growing our team. From platform engineers and AI scientists to sales, marketing, customer success, and product experts, we’re looking for top talent to join us in taking on the fight against cancer. 

View our open roles and learn more here

Our website uses cookies. By using this site, you agree to its use of cookies.